XENOPRED XENObiotic-based PREDiction platform of inter-individual differences in drug metabolism
- Coordinator
- Universita Degli Studi Di Parma, Italy
- Runs
- 1 November 2026 to 30 April 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335484
What the project is doing
In the project's own words, from its summary on CORDIS.
Inter-individual variability in drug metabolism remains a major barrier to clinical practice and drug development, often leading to adverse reactions, therapeutic inefficacy, and costly trial failures. While genetics explain only part of this variability, the contribution of the gut microbiome remains largely underestimated. The ERC-StG PREDICT-CARE project has shown that dietary (poly)phenols, a large family of plant xenobiotics metabolised through pathways that partly overlap with those involved in the metabolism of several drugs, give rise to reproducible metabolic phenotypes, defined by consistent inter-individual differences in the production of circulating phenolic metabolites and shaped by host genetics and gut microbial activity.
These metabolic profiles may therefore represent a functional readout of individual xenobiotic-metabolising capacity and could potentially be used to help predict inter-individual differences in drug metabolism. XENOPRED will investigate whether these findings can be translated into a multi-omics predictive platform designed to estimate individual drug metabolism profiles by integrating (1) PREDICT-CARE derived metabolic signatures, (2) polygenic risk scores reflecting human enzymatic capacity, and (3) microbiome-derived scores capturing microbial enzymatic potential.
It will focus on two clinically relevant phenolic drugs, ibuprofen and paracetamol, to assess the predictive accuracy, feasibility, and translational potential of this approach. Generalisability will be explored across other phenolic drugs, including irinotecan (cancer), levothyroxine (thyroid), and chlorpromazine (psychosis), for which evidence on colonic metabolism and inter-individual variability remains limited. The project aims to develop and validate an integration-ready computational module for pharmaceutical R&D workflows and future clinical decision-support tools.
By testing a safe, scalable, and cost-effective approach to stratifying individuals according to their metabolic capacity, XENOPRED aims to support safer prescribing, reduce development costs, and accelerate the uptake of personalised health solutions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Parma | Parma | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI